Aripiprazole depot

DRUG2 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc., UMC Utrecht

Conditions

Schizophrenia

Phase 3

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

CompletedNCT00705783

Otsuka Pharmaceutical Development & Commercialization, Inc.Schizophrenia

Start: 2008-07-31End: 2011-02-28Updated: 2013-07-19

Phase 4

European Long-acting Antipsychotics in Schizophrenia Trial

CompletedNCT02146547

UMC UtrechtSchizophrenia

Start: 2015-02-28End: 2020-08-26Updated: 2020-09-01

Related Papers

Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial

CNS Drugs2025-09-111 citations

Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST).

2023-01-2728 citations

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies.

2019-06-245 citations

Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies

Clinical Schizophrenia & Related Psychoses2015-02-2517 citations

EPA-0790 – All-cause discontinuation and safety of aripiprazole once-monthly for the treatment of schizophrenia: A pooled analysis of two double-blind, randomized, controlled trials

European Psychiatry2014-01-011 citations

Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.

2012-05-01137 citations